Trials / Completed
CompletedNCT01021085
Evaluation of Fetal Sex in Assisted Reproductive Technology (ART) Achieved Pregnancies
Evaluation Of A Fetal Sex Determination Test At 36-56 Days Gestation In Assisted Reproductive Technology (ART) Achieved Pregnancies
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Sequenom, Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Whole blood and urine samples will be collected from pregnant woman of gestational age 36-56 days as confirmed by artificial reproductive technology (ART). The samples will be used to develop a prenatal sex test using circulating cell free fetal DNA (ccffDNA) in maternal plasma or urine.
Detailed description
This is an observational study whereby samples will be tested to determine the presence or absence of fetal Y chromosome genes to test for the fetal sex of the baby. The blood draw and urine collection will occur between 36-42, 43-49, and 50-56 days gestation. The fetal gender will be requested at or soon after delivery. The accuracy of the test and the optimal time to perform the test during pregnancy will be assessed by comparing the test results from maternal blood and/or urine samples obtained between days 36 and 56 of gestation to the fetal sex results obtained at birth.
Conditions
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2011-08-01
- Completion
- 2011-09-01
- First posted
- 2009-11-26
- Last updated
- 2011-09-05
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01021085. Inclusion in this directory is not an endorsement.